Table 1. Characteristics of the studies included in the meta-analysis.
First author (Year) | Country | Ethnicity | Type of cancer | Source of controls | Genotyping method | Total, N | GG genotype, N | GA genotype, N | AA genotype, N | HWE | Reference | ||||
Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | ||||||||
Kong (2000) | US | Mixed | HNPCC | FB | PCR-SSCP | 49 | 37 | 9 | 10 | 36 | 21 | 4 | 6 | 0.51 | [20] |
McKay (2000) | UK | Caucasian | sCRC | PB | PCR-RFLP | 100 | 101 | 25 | 34 | 58 | 50 | 17 | 17 | 0.849 | [21] |
Bala (2001) | Finland | Caucasian | HNPCC | FB | PCR-SSCP | 146 | 186 | 50 | 47 | 70 | 97 | 26 | 42 | 0.551 | [22] |
Kong (2001) | US | Caucasian | sCRC | PB | PCR-SSCP | 156 | 152 | 36 | 45 | 71 | 84 | 49 | 23 | 0.112 | [20] |
Porter (2002) | UK | Caucasian | Mixed | PB | PCR-RFLP | 334 | 171 | 85 | 60 | 175 | 81 | 74 | 30 | 0.768 | [24] |
Porter (2002) | UK | Caucasian | HNPCC | PB | PCR-RFLP | 99 | 171 | 30 | 60 | 47 | 81 | 22 | 30 | 0.768 | [24] |
Porter (2002) | UK | Caucasian | sCRC | PB | PCR-RFLP | 128 | 171 | 34 | 60 | 65 | 81 | 29 | 30 | 0.768 | [24] |
Grieu (2003) | Australia | Caucasian | sCRC | HB | PCR-SSCP | 569 | 327 | 142 | 90 | 313 | 158 | 114 | 79 | 0.556 | [25] |
Le Marchand (2003) | US | Mixed | Mixed | PB | PCR-RFLP | 504 | 624 | 109 | 164 | 253 | 315 | 142 | 145 | 0.792 | [26] |
Le Marchand (2003) | US | Caucasian | sCRC | PB | PCR-RFLP | 138 | 161 | 29 | 50 | 75 | 85 | 34 | 26 | 0.311 | [26] |
Le Marchand (2003) | US | Asian | sCRC | PB | PCR-RFLP | 296 | 380 | 75 | 96 | 143 | 195 | 78 | 89 | 0.603 | [26] |
Lewis (2003) | US | Caucasian | sCRC | HB | PCR-RFLP | 161 | 213 | 51 | 84 | 84 | 98 | 26 | 31 | 0.781 | [27] |
Hong (2005) | Singapore | Asian | sCRC | PB | PCR-RFLP | 254 | 101 | 55 | 12 | 128 | 50 | 71 | 39 | 0.505 | [28] |
Huang (2006) | Taiwan | Asian | sCRC | HB | PCR-RFLP | 831 | 1052 | 126 | 199 | 411 | 464 | 294 | 389 | 0.004 | [29] |
Jiang (2006) | India | Asian | Mixed | HB | PCR-RFLP | 301 | 291 | 46 | 56 | 130 | 145 | 125 | 90 | 0.86 | [30] |
Kruger (2006) | Germany | Caucasian | HNPCC | PB | Multiplex PCR | 315 | 245 | 110 | 73 | 144 | 121 | 61 | 51 | 0.947 | [31] |
Probst-Hensch (2006) | Singapore | Asian | Mixed | PB | TaqMan PCR | 300 | 1169 | 56 | 207 | 132 | 548 | 112 | 414 | 0.272 | [32] |
Schernhammer (2006) | US | Caucasian | Mixed | PB | TaqMan PCR | 610 | 1237 | 125 | 264 | 311 | 593 | 174 | 380 | 0.25 | [33] |
Forones (2008) | Brazil | Mixed | Mixed | HB | PCR-RFLP | 123 | 120 | 36 | 34 | 66 | 67 | 21 | 19 | 0.141 | [34] |
Grunhage (2008) | Germany | Caucasian | Mixed | HB | PCR-RFLP | 194 | 218 | 37 | 48 | 93 | 109 | 64 | 61 | 0.958 | [35] |
Grunhage (2008) | Germany | Caucasian | HNPCC | HB | PCR-RFLP | 98 | 218 | 13 | 48 | 50 | 109 | 35 | 61 | 0.958 | [35] |
Grunhage (2008) | Germany | Caucasian | sCRC | HB | PCR-RFLP | 96 | 218 | 24 | 48 | 43 | 109 | 29 | 61 | 0.958 | [35] |
Talseth (2008) | Australia/Poland | Caucasian | HNPCC | HB | TaqMan PCR | 157 | 153 | 34 | 42 | 78 | 80 | 45 | 31 | 0.527 | [36] |
Tan (2008) | Germany | Mixed | Mixed | PB | PCR-RFLP | 498 | 600 | 120 | 147 | 263 | 310 | 115 | 143 | 0.414 | [37] |
Jelonek (2010) | Poland | Caucasian | sCC | PB | PCR-RFLP | 50 | 153 | 12 | 44 | 33 | 71 | 5 | 38 | 0.383 | [38] |
Kanaan (2010) | US | NS | sCRC | HB | PCR-HLC | 75 | 93 | 19 | 24 | 39 | 48 | 17 | 21 | 0.748 | [39] |
Liu (2010) | China | Asian | Mixed | PB | PCR-RFLP | 373 | 838 | 66 | 160 | 187 | 429 | 120 | 249 | 0.303 | [40] |
Yaylim-Eraltan (2010) | Turkey | Caucasian | Mixed | HB | PCR-RFLP | 57 | 117 | 9 | 29 | 28 | 60 | 20 | 28 | 0.781 | [41] |
HWE: Hardy–Weinberg equilibrium; US: United States; UK: United Kingdom; HNPCC: hereditary nonpolyposis colorectal cancer; sCRC: sporadic colorectal cancer; sCC: sporadic colonic cancer; FB: family-based study; PB: population-based study; HB: hospital-based study; PCR: polymerase chain reaction; SSCP: single-stranded conformation polymorphism; RFLP: restriction fragment length polymorphism; HPLC: high-performance liquid chromatography.